Following penetration of human immunodeficiency virus 1 (HIV-1) 3 into the host cell, reverse transcription of the viral RNA produces cDNA that is then integrated into the host chromosome (1). The integration of the viral cDNA is an essential early step in the HIV-1 life cycle. This reaction is catalyzed by the viral integrase (IN), a 32-kDa protein that is an integral part of the viral pre-integration complex (PIC) (2). The IN protein is encoded by the viral pol gene and is translated as part of a large Gag-Pol polyprotein that is processed by the viral protease (3, 4).For the integration process to occur, the viral IN must recognize specific sequences in the viral cDNA, at the termini of the long terminal repeat (LTR) elements. Retroviral integration proceeds in two steps: in the first, termed 3Ј-end processing, a dinucleotide is removed from the 3Ј-end. This reaction occurs in the cytoplasm, within the PIC (5, 6). In the next step, after entering the nucleus, the processed viral double-stranded DNA is joined to the host target DNA by an IN-mediated strandtransfer reaction.Due to its central role in HIV replication, the IN protein is an attractive target for antiviral therapy (4). Identifying specific IN inhibitors may provide a novel approach for multi-therapy strategies. Moreover, probably no cellular counterpart of IN exists in human cells and therefore, IN inhibitors should not interfere with normal cellular processes. However, only a few IN inhibitors have been described to date (4). This is in contrast to the number of inhibitors obtained against reverse transcriptase (RT) and the protease, which are the other HIV-1 enzymes that are currently used as targets for the development of anti-HIV-1 drugs (4). A promising approach for the discovery of IN inhibitors is the use of peptides derived from the IN-binding sequences of IN-interacting proteins.Specific domains within viral proteins are responsible for their interaction with host-cell receptors and with other viral and cellular proteins enabling the completion of the viral propagation cycle within the host cell (1, 6). Peptides derived from these binding domains may interfere with virus-host and virusvirus protein interactions and as such are excellent candidates as therapeutic agents. Using this approach, short peptides that inhibit IN enzymatic activity were obtained following analysis of the interaction between two of the HIV-1 proteins, RT and IN. Screening a complete library of RT-derived peptides demonstrated that two domains of about 20 amino acids mediate this interaction. Peptides bearing these amino acid sequences blocked IN enzymatic activities in vitro (7).In the present work, we observed a not yet described interaction between the HIV-1 Rev and IN proteins. The HIV-1 Rev is a karyophilic protein, which is required at the late phase of the viral life cycle for promoting nuclear export of partially spliced or un-spliced viral RNA (8, 9). Based on this finding, we identi-* This work was supported in part by grants from the Israel Science Foundat...